teacup. [ 掲示板 ] [ 掲示板作成 ] [ 有料掲示板 ] [ ブログ ]

 投稿者
  題名
  内容 入力補助画像・ファイル<IMG> youtubeの<IFRAME>タグが利用可能です。(詳細)
    
 URL
[ ケータイで使う ] [ BBSティッカー ] [ 書込み通知 ]


(無題)

 投稿者:名無しのリーク  投稿日:2016年 7月 2日(土)05時20分30秒
返信・引用
  香川県ルー餃子のフジフーヅはバイトにパワハラの末指切断の大けがを負わせた糞ブラック企業  
 

ハンガリ国ラブテック社12誘導心電計

 投稿者:メディカルテクニカ  投稿日:2015年 1月30日(金)14時05分35秒
返信・引用
  創薬研究システムをご提案

http://www.medicalteknika.jp/

 

第二回12誘導心電図伝送を考える会

 投稿者:ラブテック社モバイル心電計  投稿日:2014年10月31日(金)08時00分24秒
返信・引用
  関連デバイスのメーカの併設展示有り、プレゼンテーションできます

http://clcard.umin.jp/

 

アルテリオグラフの長所

 投稿者:Arterial Stiffness  投稿日:2014年 7月 8日(火)14時21分56秒
返信・引用
  Gordons Chemists Launch a new Cardiovascular Screening Clinic
23 May 2014 12:19:30

CardioHealth NI ? Give your arteries an MOT!

Gordons Chemists are pleased to offer a new cardiovascular screening clinic.
Statistics indicate that around 60% of the time in heart attack cases, a standard cholesterol or blood pressure test won’t have revealed anything out of the ordinary. Guidelines (published in 2007) from the European Society of Hypertension recommend measuring arterial stiffness in patients with arterial hypertension (high blood pressure).
Gordons Chemists are pleased to offer across Northern Ireland a cardiovascular screening clinic, using a state-of-the-art arteriograph. CardioHealth NI is the first and only company in Northern Ireland that uses an arteriograph; a session with CardioHealth NI at one of our cardiovascular screening clinics is priced at only £50.
A cardiovascular screening using an arteriograph reveals much more than a typical blood pressure or cholesterol test will. By offering this cardiovascular screening clinic, we allow the patient to have a better understanding of the health of their arteries. As such they can make the decision to take control of their cardiovascular health ? hopefully reducing the incidence or severity of heart attack, stroke or high blood pressure.
In addition to identifying underlying health problems, the screening includes recommendations on diet and natural health solutions. A detailed report allows the patient to consult with their GP or medical professional in order to seek further advice and treatment, based on the findings of the screening.
The cardiovascular screening clinic is suitable for anyone aged 16 years and over, or anyone with a family history of heart disease, kidney disease or diabetes. It’s also suitable for anyone who drinks alcohol or smokes, is overweight, or participates in (or is returning to) a sport.

About the Arteriograph
An arteriograph is a sophisticated instrument used for detecting changes to the artery walls. The arteriograph uses a cuff that contains special pressure sensors.
These pressure sensors are designed to detect the Pulse Wave (pressure wave) that leaves the heart as it contracts. When the pulse wave reaches the end of the arterial system, it is then reflected back towards the heart. Three key measurements are taken from this pulse wave.
An arteriograph reveals damage to the heart and arteries that a standard blood pressure or cholesterol test will not. It measures parameters that indicate if the patient might at risk of heart attack or stroke, including:
Central Systolic Blood Pressure
This in effect measures blood pressure, at the heart. Studies indicate that this is of greater value than measuring blood pressure on the arm.
Brachial Augmentation
This reveals early damage to, and clogging up of, your smaller arteries. When arterial clogging begins, it occurs firstly in the small arteries of the hands and feet. This can be measured and it indicates the degree of clogging and the damage to the inner lining of your smaller arteries.
Pulse Wave Velocity
The speed of the pressure wave described above is measured over a given distance. An increased speed indicates a clogging of the arteries. There is a direct correlation between this, and an increased risk of heart attack/stroke. The reading is often found to be abnormal in patients with kidney disease, diabetes, sufferers of rheumatoid arthritis, and smokers.
The Arteriograph is a new, easy-to-use, and time-effective method for assessing arterial stiffness. Prior to the arteriograph, there were (and still are) two invasive methods used within a hospital setting: the tonometric and piezo-electronic systems (SphygmoCor and Complior).
An arteriograph is not intended as a replacement for these. Instead, the device is intended for use as a quick, affordable and non-invasive means of diagnosing an underlying condition that the patient may not be aware of. Clinical trials (see below for details) reveal that an arteriograph gives accurate results (which are comparable to the two systems mentioned).
The main advantage of using an arteriograph is that it offers a quick and affordable assessment, using only the upper arm.
Other methods involve a detailed examination and take time to complete. Typically, these (due to the time and expense involved in completing a screening) aren’t readily available at the request of a patient.
CardioHealth NI’s cardiovascular screening clinics offer the patient the opportunity to have a detailed and accurate assessment of their cardiovascular system completed ? at a relatively low price, in a location close to them, in just half an hour.
Upcoming clinic detail can be obtained by emailing: info@gordonsdirect.com

Clinical Evidence
Publications on the validation of the Arteriograph device:
? Baulmann, J. et al.
? "A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezo-electronic methods"
? J Hypertens 2008, 26:523-528
? http://www.arteriograph.hu/downloads/pdf/Baulmann%20validation-J-Hypert%2708March-Cover.pdf

? Jatoi, N.A., et al.
? “Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques”
? J Hypertens 2009, 27:2186?2191
? http://www.arteriograph.hu/downloads/pdf/Mahmud-Feely-Compl-Sphygm-Art-JHypert-Oct%2709.pdf

? Boutouyrie P, Revera M and Parati G.
? “Obtaining arterial stiffness indices from simple arm cuff measurements: the holy grail?”
? J Hypertension 2009; 27:2159-2161
? http://www.arteriograph.hu/downloads/pdf/Boutouyrie-Editorial-JHypert-Oct%2709.pdf

? Rajzer MW, Wojciechowska W, Klocek M, Palka I, Brzozowska-Kiszka M, Kawecka-Jaszcz K.
? “Comparison of aortic pulse wave velocity measured by three techniques: Complior, SphygmoCor and Arteriograph.”
? J Hypertens 2008; 26:2001-7
? http://www.arteriograph.hu/downloads/pdf/Marek%20Rajzer%20comp%20study%20with%20ARG.pdf

? Horváth, G.I. et al
? “Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity”
? J Hypertens 2010, 28:2068?2075
? http://www.arteriograph.hu/downloads/pdf/Invasive%20validation%20JoH%202010%2028.pdf

? Parati G, Buyzere de M
? “Evaluating aortic stiffness through an arm cuff oscillometric device: is validation against invasive measurements enough?"
? Journal of Hypertension 2010, 28:2003?2006
? http://www.arteriograph.hu/downloads/pdf/Parati%20Editorial%20Comment%20on%20invasive%20validation.pdf



http://medicallabtech.digi2.jp/tensiomedguide/

 

高血圧

 投稿者:動脈硬化  投稿日:2014年 5月31日(土)00時52分9秒
返信・引用
  武田薬品の広告が患者に与えた不利益は甚大 CASE-J試験の疑惑を指摘してきた桑島巖医師に聞く

(C)東洋経済オンライン
 医師主導臨床試験をめぐる不祥事が次々と持ち上がり、産学協同への信頼が大きく低下している。ノバルティスファーマによる不正に続き、3月3日には武田薬品工業が高血圧症治療薬ブロプレス(一般名カンデサルタン)のセールスプロモーション(販売促進活動)を不正確なデータを用いて7年以上にわたって続けていたことが発覚。同社の長谷川閑史社長自ら、「日本製薬工業協会が定めたプロモーション規約に違反していた」と認めて謝罪した。
 カンデサルタンを初めとする高血圧症治療薬の医師主導臨床試験に疑問を投げ掛けてきた桑島巖医師(NPO法人臨床研究適正評価教育機構理事長、東京都健康長寿医療研究センター顧問)に、問題の所在について聞いた。
以前から問題点を指摘してきた
――武田薬品が37億円にのぼる多額の寄付金を拠出した医師主導臨床試験CASE-Jでも、不正疑惑が持ち上がりました。

 CASE-J試験は、ノバルティスファーマが関与したKYOTO HEART試験やJIKEI HEART試験と並んでおかしな点が多いと以前から私は指摘してきた。詳しくは「循環器トライアルデータベース」というインターネットサイトに私が書いたコメントが掲載されているので見てほしい。
そこに記述したが、武田薬品の高血圧薬カンデサルタンと他社のアムロジピンの2群間の比較において、カンデサルタンを投与された患者群のほうが明らかに多くの高血圧薬を併用していることが、2008年に発表されたCASE-Jの主論文から明らかになっている。このことは、ほかのたくさんの薬剤を服用しなければ、アムロジピン投与群と同等の降圧効果を得られないことを証明している。
エンドポイント(評価項目)の内訳を見るとわかるが、カンデサルタンが優位な狭心症やTIA(一過性脳虚血発作)などは、客観性の乏しいエンドポイントである。これらの項目には臨床試験にかかわった医師の主観が働きやすく、この点でも企業支援による非盲検試験に特有の問題点が浮かび上がってくる。
――学会発表データを元に武田薬品の企画広告で作成されたグラフでは、治療を開始して36カ月まではアムロジピンを投与した患者のほうが心血管イベントの発症率が少なかったものの、36カ月を境に逆転し、カンデサルタンのほうが好成績になっていました。

 試験開始からしばらくの間はアムロジピン群のほうが血圧の低下が大きいから、脳卒中や心筋梗塞などの心血管イベントの抑制に効果があったと考えられる。それが途中から逆転することは考えにくく、何らかの操作の疑いを抱かせる。グラフの形もきわめて不自然だ。(CASE-J試験の運営を受託した)研究センターから発行されたニュースレターをみると血圧が高い場合には併用禁止薬を投与してよいことになっているが、それらを統計上どのように扱ったかが問題である。
薬事法違反の誇大広告に該当も
――武田薬品は、学会発表のデータを販売促進活動に使用したことは、日本製薬工業協会のプロモーション規約に違反する不適切な行為だったと認めました。

 それ自体はそうだろうが、薬事法違反の誇大広告にも当たるのではないか。アムロジピンのほうが薬の値段が安いうえに、降圧効果が大きい。にもかかわらず、誤った情報を元に、カンデサルタン服用にメリットがあると最近までPRしてきたのだから、患者さんに与えた不利益はきわめて大きいと思われる。

 

Arterial Stiffness

 投稿者:メディカルテクニカ  投稿日:2014年 5月18日(日)11時52分59秒
返信・引用
  文献ご発表にご活用をご期待しております
ワイヤレス ブルーツース 24時間から72時間計測 三分計測
世界特許有り 文献多数 薬事認可済

Arterial Assessment Validation Publications

Baulmann, J. et al.
“A new oscillometric method for assessment of arterial stiffness: comparison with tonometric and piezoelectronic methods”
J Hypertension 2008, 26:523-528

Jatoi, N.A., et al.
“Assessment of arterial stiffness in hypertension: comparison of oscillometric (Arteriograph), piezoelectronic (Complior) and tonometric (SphygmoCor) techniques”
H Hypertension 2009, 27:2186-2191

Boutouyrie P, Revera M and Parati G.
“Obtaining arterial stiffness indices from simple arm cuff measurements: the holy grail?”
J Hypertension 2009; 27: 2159-2161

Rajzer MW, Wojciechowska W, Klocek M, Palka I, Brzozowska-Kiszka M, Kawecka-Jaszcz K.
“Comparison of aortic pulse wave velocity measured by three techniques: Coplior, SphygmoCor and Arteriograph.”
J Hypertension 2008; 26:2001-7

Horvath, G.I. et al.
“Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity.:
J Hypertension 2010, 28:2068-2075

Parati G, Buyzere de M
“Evaluating aortic stiffness through an arm cuff oscillometric device: is validation against invasive measurements enough?”
Journal of Hypertension 2010, 28:2003-2006

http://homepage2.nifty.com/medicalteknika/tensiomedguide/

 

Arterial Stiffness

 投稿者:メディカルテクニカ  投稿日:2014年 5月18日(日)11時50分59秒
返信・引用
  文献ご発表にご活用をご期待しております
ワイヤレス ブルーツース 24時間から72時間計測 三分計測
世界特許有り 文献多数 薬事認可済

The Scientific World Journal
Volume 2013 (2013), Article ID 792693, 6 pages
http://dx.doi.org/10.1155/2013/792693
Clinical Study
Evaluation of Arterial Stiffness for Predicting Future Cardiovascular Events in Patients with ST Segment Elevation and Non-ST Segment Elevation Myocardial Infarction
Oguz Akkus,1 Durmus Yildiray Sahin,2 Abdi Bozkurt,3 Kamil Nas,4 Kazım Serhan Ozcan,1 Miklós Illyés,5 Ferenc Molnár,6 Serafettin Demir,7 Mücahit Tüfenk,3 and Esmeray Acarturk3
1Sanliurfa Siverek State Hospital, 63600 Sanliurfa, Turkey
2Department of Cardiology, Adana Numune Training and Research Hospital, Adana, Turkey
3Department of Cardiology, Faculty of Medicine, Cukurova University, Adana, Turkey
4Department of Radiology, Szent János Hospital, Budapest, Hungary
5Heart Institute, Faculty of Medicine, University of Pécs, Pécs, Hungary
6Department of Hydrodynamic Systems, Budapest University of Technology and Economics, Budapest, Hungary
7Department of Cardiology, Adana State Hospital, Adana, Turkey
Received 18 August 2013; Accepted 15 September 2013
Academic Editors: H. Kitabata and E. Skalidis
Copyright © 2013 Oguz Akkus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background. Arterial stiffness parameters in patients who experienced MACE after acute MI have not been studied sufficiently. We investigated arterial stiffness parameters in patients with ST segment elevation (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI). Methods. Ninety-four patients with acute MI (45 STEMI and 49 NSTEMI) were included in the study. Arterial stiffness was assessed noninvasively by using TensioMed Arteriograph. Results. Arterial stiffness parameters were found to be higher in NSTEMI group but did not achieve statistical significance apart from pulse pressure . There was no significant difference at MACE rates between two groups. Pulse pressure and heart rate were also significantly higher in MACE observed group. Aortic pulse wave velocity (PWV), aortic augmentation index (AI), systolic area index (SAI), heart rate, and pulse pressure were higher; ejection fraction, the return time (RT), diastolic reflex area (DRA), and diastolic area index (DAI) were significantly lower in patients with major cardiovascular events. However, PWV, heart rate, and ejection fraction were independent indicators at development of MACE. Conclusions. Parameters of arterial stiffness and MACE rates were similar in patients with STEMI and NSTEMI in one year followup. The independent prognostic indicator aortic PWV may be an easy and reliable method for determining the risk of future events in patients hospitalized with acute MI.
1. Introduction
Acute myocardial infarction (AMI) continues a worldwide cause of mortality [1]. In-hospital and 6-month-mortality are approximately 5?7% versus 12-13%, respectively [2, 3]. Estimated risk of mortality for AMI is based on the clinical status of the patients [4]. Recent studies showed that conventional risk factors are inadequate for predicting cardiovascular (CV) mortality and morbidity. A novel risk factor called arterial stiffness, which is a defined reduction of the compliance of arterial wall, and relationship between coronary heart disease (CHD) have been demonstrated. Arterial stiffness results in faster reflection of the forward pulse wave from bifurcation points in peripheral vessels. As a result of new waveform, systolic blood pressure (SBP) increases, diastolic blood pressure (DBP) decreases, cardiac workload increases, and coronary perfusion falls down. It plays a major role in the determination of cardiovascular outcomes, and it is not inferior to the traditional risk factors to assess the future risk [5, 6]. Elevated arterial stiffness is associated with increased major adverse cardiovascular events (MACE) such as unstable angina, AMI, coronary revascularization, heart failure, stroke, and death [7]. Arterial stiffness parameters including mean arterial pressure (MAP), pulse pressure (PP), PWV (m/s), and augmentation index (AI) are directly proportional to the risk of MACE [8?10].
PWV is a susceptible diagnostic element, and it is also involved in risk stratification for subclinical organ damages [11]. Few studies regarding arterial stiffness demonstrated that PWV exhibits a close effect with coronary heart disease [5, 12, 13]. Whether arterial stiffness parameters are related to MACE after acute MI has not been studied sufficiently. The aim of our study was to compare arterial stiffness parameters in patients with ST segment elevation (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI) and to validate its prognostic value.
2. Patients
Ninety-four patients with acute MI (72 men and 22 women, mean age 60,41 ± 11,17) were included in the study. There were 45 STEMI and 49 NSTEMI. Data of patients were analyzed within 24 hours after hospitalization. All patients received eligible treatment according to ESC guidelines. The choice of preparations was entrusted to the investigator. Hemodynamically compromised patients (Killip classifications II, III, and IV), patients with chronic atrial fibrillation and/or flutter, chronic renal failure, mild-severe valvular heart diseases and other chronic diseases were excluded. Our local ethics committee approved the study, and written informed consent was obtained from all participants. Patients were followed up for 12 months.
3. Diagnosis of Acute Myocardial Infarction
Diagnosis of AMI was based on symptoms, elevated cardiac markers, and electrocardiogram (ECG) changes. Patients with typical chest pain plus ECG changes indicative of an AMI (pathologic Q waves, at least 1?mm ST segment elevation in any 2 or more contiguous limb leads or new left bundle branch block, or new persistent ST segment and T wave changes diagnostic of a non-Q wave myocardial infarction) or a plasma level of cardiac troponin-T level above normal.
4. Laboratory Findings
Troponin T, creatine kinase-MB fraction (CK-MB), serum urea, creatinine, eGFR, and other hematological parameters were checked at the admission.
Risk factors, such as hypertension, hyperlipidemia, diabetes mellitus, cigarette smoking, and family history, were recorded. Hypertension was considered as SBP and DBP greater than 140?mmHg and 90?mmHg, respectively, using an antihypertensive medication. Diabetes mellitus, hyperlipidemia, and hypertriglyceridemia were defined as using antidiabetic drugs or fasting blood glucose over 126?mg/dL, as plasma low-density lipoprotein cholesterol (LDL-C) >130?mg/dL, using lipid-lowering drugs at the time of investigation, and as TG level >150?mg/dL, respectively, according to the Third Report of the National Cholesterol Education Program guidelines. First-degree relatives who are exposed to coronary artery disease (CAD) before the age for male is <55 and female <65 were considered as family history.
5. Pulse Waveform Analysis
Assessment of arterial stiffness was performed noninvasively with the commercially available TensioMed Arteriograph. We collected the oscillometric pulse waves from the patients. We measured the distance between the jugulum-symphysis (which is equal to the distance between the aortic root and the aortic bifurcation), and PWV was calculated. Pulse waves were recorded at suprasystolic pressure. The oscillation signs were identified from the cuff inflated at least >35?mmHg above the systolic blood pressure. In this state there was a complete brachial artery occlusion, and it functions as a membrane before the cuff. Pulse waves hit the membrane, and oscillometric waves were measured by the device and we could see the waveforms on the monitor. The AI was defined as the ratio of the difference between the second (P2 appearing because of the reflection of the first pulse wave) and first systolic peaks (P1 induced by the heart systole) to pulse pressure (PP), and it was expressed as a percentage of the ratio (AI = [P2 - P1]/PP × 100). SBP, DBP, PP, and heart rate and other hemodynamic parameters as return time (RT in sec.), diastolic reflection area (DRA), systolic area index (SAI %), and diastolic area index (DAI %) were measured noninvasively. DRA reflects the quality of the coronary arterial diastolic filling (SAI and DAI are the areas of systolic and diastolic portions under the pulse wave curve of a complete cardiac cycle, resp.). Hence, the bigger the DAI and DRA are, the better the coronary perfusion is. Furthermore, RT is the PWV time from the aortic root until the bifurcation and return, so this value is smaller as the aortic wall is stiffer.

http://homepage2.nifty.com/medicalteknika/tensiomedguide/

 

Arterial Stiffness

 投稿者:メディカルテクニカ  投稿日:2014年 5月18日(日)11時40分17秒
返信・引用
  文献ご発表にご活用をご期待しております
ワイヤレス ブルーツース 24時間から72時間計測 三分計測
世界特許有り 文献多数 薬事認可済

Am J Hypertens. 2013 Aug 31. [Epub ahead of print]
Invasive Validation of Arteriograph Estimates of Central Blood Pressure in Patients With Type 2 Diabetes.
Rossen NB, Laugesen E, Peters CD, Ebbehøj E, Knudsen ST, Poulsen PL, Bøtker HE, Hansen KW.
Author information
? Department of Medicine, Silkeborg Regional Hospital, Silkeborg, Denmark.
Abstract
BACKGROUND:
Central blood pressure (BP) has attracted increasing interest because of a potential superiority over brachial BP in predicting cardiovascular morbidity and mortality. Several devices estimating central BP noninvasively are now available. The aim of our study was to determine the validity of the Arteriograph, a brachial cuff-based, oscillometric device, in patients with type 2 diabetes.
METHODS:
We measured central BP invasively and compared it with the Arteriograph-estimated values in 22 type 2 diabetic patients referred to elective coronary angiography.
RESULTS:
The difference (invasively measured BP minus Arteriograph-estimated BP) in central systolic BP (SBP) was 4.4±8.7mm Hg (P = 0.03). The limits of agreement were ±17.1mm Hg.
CONCLUSIONS:
Compared with invasively measured central SBP, we found a systematic underestimation by the Arteriograph. However, the limits of agreement were similar to the previous Arteriograph validation study and to the invasive validation studies of other brachial cuff-based, oscillometric devices. A limitation in our study was the large number of patients (n = 14 of 36) in which the Arteriograph was unable to analyze the pressure curves. In a research setting, the Arteriograph seems applicable in patients with type 2 diabetes.
CLINICAL TRAIL REGISTRATION:
ClinicalTrials.gov ID NCT01538290.
KEYWORDS:
blood pressure, brachial cuff-based, oscillometric devices for measurement of central BP, cardiovascular disease, cardiovascular risk, central blood pressure (BP), diabetes, hypertension, invasive validation of brachial cuff-based, oscillometric devices noninvasive measurement of central BP.

http://homepage2.nifty.com/medicalteknika/tensiomedguide/

 

Arterial Stiffness

 投稿者:メディカルテクニカ  投稿日:2014年 5月18日(日)11時33分4秒
返信・引用
  文献ご発表にご活用をご期待しております
ワイヤレス ブルーツース 24時間から72時間計測 三分計測
世界特許有り 文献多数 薬事認可済

Hypertension Research (2011) 34, 202?208; doi:10.1038/hr.2010.196; published online 21 October 2010
Can arterial stiffness parameters be measured in the sitting position?
Jens Nürnberger1, Rene Michalski2, Tobias R Türk2, Anabelle Opazo Saez1, Oliver Witzke2 and Andreas Kribben2
1. 1Department of Nephrology and Dialysis, HELIOS Kliniken Schwerin, Wismarsche Straße, Schwerin, Germany
2. 2Department of Nephrology, University Hospital Essen, University Essen-Duisburg, Hufelandstraße, Essen, Germany
Correspondence: Dr J Nürnberger, Department of Nephrology, HELIOS Kliniken Schwerin, Wismarsche Straße 393-397, Schwerin 19049, Germany. E-mail: jens.nuernberger@uni-due.de
Received 2 May 2010; Revised 25 July 2010; Accepted 31 July 2010; Published online 21 October 2010.
Top of page
Abstract
Despite the introduction of arterial stiffness measurements in the European recommendation, pulse wave velocity (PWV) and augmentation index (AI) are still not used routinely in clinical practice. It would be of advantage if such measurements were done in the sitting position as is done for blood pressure. The aim of this study was to evaluate whether there is a difference in stiffness parameters in sitting vs. supine position. Arterial stiffness was measured in 24 healthy volunteers and 20 patients with cardiovascular disease using three different devices: SphygmoCor (Atcor Medical, Sydney, Australia), Arteriograph (TensioMed, Budapest, Hungary) and Vascular Explorer (Enverdis, Jena, Germany). Three measurements were performed in supine position followed by three measurements in sitting position. Methods were compared using correlation and Bland?Altman analysis. There was a significant correlation between PWV in supine and sitting position (Arteriograph: P<0.0001, r=0.93; Vascular Explorer; P<0.0001, r=0.87). There were significant correlations between AI sitting and AI supine using Arteriograph (P<0.0001, r=0.97), Vascular Explorer (P<0.0001, r=0.98) and SphygmoCor (P<0.0001, r=0.96). When analyzed by Bland?Altman, PWV and AI measurements in supine vs. sitting showed good agreement. There was no significant difference in PWV obtained with the three different devices (Arteriograph 7.5±1.6?m?s-1, Vascular Explorer 7.3±0.9?m?s-1, SphygmoCor 7.0±1.8?m?s-1). AI was significantly higher using the Arteriograph (17.6±15.0%) than Vascular Explorer and SphygmoCor (10.2±15.1% and 10.3±18.1%, respectively). The close agreement between sitting and supine measurements suggests that both PWV and AI can be reliably measured in the sitting position.
Keywords:
arterial stiffness; augmentation index; PWV; pluse wave velocity

http://homepage2.nifty.com/medicalteknika/tensiomedguide/

 

Arterial Stiffness

 投稿者:メディカルテクニカ  投稿日:2014年 5月18日(日)11時31分29秒
返信・引用
  文献ご発表にご活用をご期待しております
ワイヤレス ブルーツース 24時間から72時間計測 三分計測
世界特許有り 文献多数 薬事認可済


American Journal of Hypertension
ajh.oxfordjournals.org
Am J Hypertens (2005) 18 (S4): 15A. doi: 10.1016/j.amjhyper.2005.03.035
P-17: A new and fast screening method for measuring complex hemodynamical parameters and arterial stiffness non-invasively with a simple arm cuff
Miklos Illyes1
+ Author Affiliations
1TensioMed Ltd., TensioMed Ltd, Budapest, Hungary
Abstract
Aims: In a project of the National Research Program of Hungary, we studied if oscillometric signals received during an oscillometric BP measurement contain any information about arterial hemodynamics
Materials, Methods: We have developed a research tool by which not only SBP, DBP, HR data, but the complete oscillometric signals were stored and transmitted telemedically to our computer center from the home of 650 patients who performed BP measurements at least 4 times a day, for at least 1 month. Through this a large database was collected, containing more than 1700000 oscillometric pulse curves and the relevant clinical data of patients. For data mining we used Kohonen's self-organising map method. Non-invasively recorded oscillometric curves from the upper arm cuff were validated by the simultaneously recorded intraarterial pressure curve of brachial artery.
Results: Our researches showed that oscillometric pulse curve of the brachial artery is identical to the intraarterial pressure curve if the cuff was inflated to suprasystolic pressure, preferably 35 mmHg above the SBP. Thus the early and the late systolic pressure peak, the closing incisure of the aortic valve can be recognizable, and several hemodinamical parameters could be calculated.
By using the mentioned results of basic researches, a new instrument, the TensioClinic Arteriograph was developed, by which the following parameters could be measured within 2 minutes, by using a simple upper arm cuff:
SBP, DBP, HR, MAP, PP, augmentation index (AIx), normalized augmentation index to 80/min heart rate (AIx80), return time of the pulse wave of the aorta (RT), pulse wave velocity (PWV) of the aorta, length of the cardiac cycle, area of systolic (SAI) and diastolic (DAI) part of pulse curve.
Validation studies of the new method to control the accuracy of measured AIx and PWV showed high correlations (R = 0,76 and R = 0,8) with values measured with other non-invasive methods (Sphygmocor and Complior) respectively.
Conclusions: Due to the swiftness, simplicity and good reproducibility of this method and apparatus, the non-invasive assessment of the most important hemodynamical parameters and arterial stiffness had become available for population screening, opening a new window in the detection of the early phase of the athero- and arteriosclerosis, and thus it can play an important role in the reduction of the CV morbidity and mortality.

http://homepage2.nifty.com/medicalteknika/tensiomedguide/

 

レンタル掲示板
/33